Skip to content

Effect of Nasya (nasal inhalation) on metabolic and immunological markers in patients suffering from Purana peenasa (chronic rhinitis)

A prospective, assessor blind, open, parallel group study to observe the effects of Nasya on selected metabolic land immunological markers in patients suffering from chronic allergic rhinitis.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/09/002964
Enrollment
30
Registered
2012-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- nasal discharge

Interventions

Intervention1: Nasya: Nasya (nasal administration of medicines). In the dose of 4/ 6/ 8 drops per day in each nostril. The dose is decided by the attending physician everyday. The procedure was carrie

Sponsors

Principal Science Advisor Prime Minister Office Govt of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient having classical signs and symptoms of Purana Peenasa such as nasastrava (nasal discharge), shirogurutva (heaviness in the head), anaddha nasa (feeling of obstruction in the nose), kshavathu (sneezing) intermittently for more than 1 year. 2. Patient complains of aggravation of the above symptoms due to inhalant allergens. 3. Patient is ready to abide by trial procedures and to give informed consent

Exclusion criteria

Exclusion criteria: 1. Patient requiring acute medical care 2. Patient complaining of or giving the h/o Sinusitis, grossly Deviated Nasal, Septum or Nasal Polyp. 3. Patient with multi-organ involvement, cardiac, respiratory, hepatic and renal disease. 4. Pregnant and lactating women (in women of child bearing age, a urine pregnancy test will be performed to rule out pregnancy). 5. Patients with nava pratishya (acute coryza), nava jwara (acute fever), kasa (cough) and swasa (difficulty in breathing). 6. Patient who have experienced any Panchakarma Vyapad (unwanted effects/ complications previously). 7. Patient who have received any of the Panchakarma procedure in last 2 months.

Design outcomes

Primary

MeasureTime frame
1. Changes in metabolic and immunological status of the Volunteer 2. Improvement in the Quality of life assessment will be done by using standard Health, Wellness and Quality of life questionnaire.Timepoint: 0 day, immediately after completion of procedures and 90 days after completion of procedures

Secondary

MeasureTime frame
decrease in gradations of Clinical assessment.Timepoint: 0 day, immediately after completion of procedures and 90 days after completion of procedures

Countries

India

Contacts

Public ContactDr Urmila Thatte

Seth GS Medical College and KEM Hospital

urmilathatte@gmail.com02224133767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026